EUVIMEDEUVIMED entdecken
Crossref

Limitations in the clinical utility of vaccine challenge responses in the evaluation of primary antibody deficiency including Common Variable Immunodeficiency Disorders

Rohan Ameratunga, Hilary Longhurst, Euphemia Leung, Richard Steele, Klaus Lehnert, See-Tarn Woon

Clinical Immunology · 2024

DOI: 10.1016/j.clim.2024.110320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2024. Verfasst von Rohan Ameratunga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Auckland Hospital, Park Rd, Grafton, 1010, Auckland, New Zealand; Department of Virology and Immunology, Auckland …. Hauptthemen laut MEDLINE: Common Variable Immunodeficiency, Pneumococcal Vaccines, Haemophilus Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Auckland District Health Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccine challenge responses are an integral component in the diagnostic evaluation of patients with primary antibody deficiency, including Common Variable Immunodeficiency Disorders (CVID). There are no studies of vaccine challenge responses in primary hypogammaglobulinemia patients not accepted for subcutaneous/intravenous immunoglobulin (SCIG/IVIG) replacement compared to those accepted for such treatment. Vaccine challenge responses in patients enrolled in two long-term prospective cohorts, the New Zealand Hypogammaglobulinemia Study (NZHS) and the New Zealand CVID study (NZCS), were compared in this analysis. Almost all patients in the more severely affected SCIG/IVIG treatment group achieved protective antibody levels to tetanus toxoid and H. influenzae type B (HIB). Although there was a highly significant statistical difference in vaccine responses to HIB, tetanus and diphtheria toxoids, there was substantial overlap in both groups. In contrast, there was no significant difference in Pneumococcal Polysaccharide antibody responses to Pneumovax® (PPV23). This analysis illustrates the limitations of evaluating vaccine challenge responses in patients with primary hypogammaglobulinemia to establish the diagnosis of CVID and in making decisions to treat with SCIG/IVIG. The conclusion from this study is that patients with symptoms attributable to primary hypogammaglobulinemia with reduced IgG should not be denied SCIG/IVIG if they have normal vaccine responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Common Variable ImmunodeficiencyPneumococcal VaccinesHaemophilus VaccinesHumansFemaleMaleMiddle AgedAdultAntibodies, BacterialAgammaglobulinemiaImmunoglobulins, IntravenousProspective StudiesTetanus ToxoidAgedYoung AdultAdolescentNew ZealandChildHaemophilus influenzae type b

Stichwörter der Autor:innen

CVIDCohort studiesHypogammaglobulinemiaSCIG/IVIGVaccine challenge responses

Substanzen

Pneumococcal VaccinesHaemophilus VaccinesAntibodies, BacterialImmunoglobulins, IntravenousTetanus Toxoid

Autor:innen und Institutionen

  • Department of Clinical Immunology, Auckland Hospital, Park Rd, Grafton, 1010, Auckland, New Zealand; Department of Virology and Immunology, Auckland Hospital, Park Rd, Grafton, 1010 Auckland, New Zealand; Department of…
  • Department of Virology and Immunology, Auckland Hospital, Park Rd, Grafton, 1010 Auckland, New Zealand; Department of Medicine, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Park Rd…
  • Maurice Wilkins Centre, School of Biological Sciences, University of Auckland, Symonds St, Auckland, New Zealand; Auckland Cancer Society Research Centre, School of Medicine, Faculty of Medical and Health Sciences, Univ…
  • Department of Virology and Immunology, Auckland Hospital, Park Rd, Grafton, 1010 Auckland, New Zealand; Department of Respiratory Medicine, Wellington Hospital, Wellington, New Zealand.
  • Department of Respiratory Medicine, Wellington Hospital, Wellington, New Zealand; Applied Translational Genetics, School of Biological Sciences, University of Auckland, Auckland, New Zealand; Centre for Brain Research,…
  • Department of Virology and Immunology, Auckland Hospital, Park Rd, Grafton, 1010 Auckland, New Zealand; Department of Molecular Medicine and Pathology, School of Medicine, Faculty of Medical and Health Sciences, Univers…

Förderung

  • Auckland District Health Board

Zitieren

APA

Ameratunga, R., Longhurst, H., Leung, E., Steele, R., Lehnert, K., & Woon, S. T. (2024). Limitations in the clinical utility of vaccine challenge responses in the evaluation of primary antibody deficiency including Common Variable Immunodeficiency Disorders. Clinical Immunology. https://doi.org/10.1016/j.clim.2024.110320

Vancouver

Ameratunga R, Longhurst H, Leung E, Steele R, Lehnert K, Woon ST. Limitations in the clinical utility of vaccine challenge responses in the evaluation of primary antibody deficiency including Common Variable Immunodeficiency Disorders. Clinical Immunology. 2024. doi:10.1016/j.clim.2024.110320

BibTeX
@article{Ameratunga2024,
  author = {Ameratunga, Rohan and Longhurst, Hilary and Leung, Euphemia and Steele, Richard and Lehnert, Klaus and Woon, See-Tarn},
  title = {Limitations in the clinical utility of vaccine challenge responses in the evaluation of primary antibody deficiency including Common Variable Immunodeficiency Disorders},
  journal = {Clinical Immunology},
  year = {2024},
  doi = {10.1016/j.clim.2024.110320}
}
Kostenlos starten →